Logo

COEPW

Coeptis Therapeutics Holdings, Inc.

COEPW

Coeptis Therapeutics Holdings, Inc. • NASDAQ
$0.02 ▲ 21.71% (+0.00)
Market Cap $98792
52w High $0.02
52w Low $0.01
Dividend Yield 0%
P/E 0
Volume 10.55K
Outstanding Shares 5.34M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $237.441K ▲ $2.669M ▼ $-159.36K ▲ -67.116% ▲ $-0.577 ▲ $-2.53M ▲
Q2-2025 $200.681K ▲ $4.677M ▲ $-3.535M ▼ -1.761K% ▲ $-0.954 ▲ $-3.961M ▼
Q1-2025 $62.874K ▲ $2.76M ▲ $-3.058M ▼ -4.863K% ▼ $-0.995 ▲ $-3.044M ▼
Q4-2024 $0 $1.902M ▲ $-3.012M ▼ 0% $-1.423 ▼ $-2.673M ▼
Q3-2024 $0 $1.71M $-1.829M 0% $-0.919 $-1.5M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $5.33M ▲ $16.282M ▲ $3.265M ▼ $12.466M ▲
Q2-2025 $2.987M ▼ $12.191M ▼ $5.111M ▼ $6.096M ▼
Q1-2025 $4.268M ▲ $13.453M ▲ $5.99M ▲ $6.479M ▲
Q4-2024 $532.885K ▼ $8.909M ▼ $5.041M ▲ $3.185M ▼
Q3-2024 $1.137M $8.956M $3.974M $4.825M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-2.739M ▲ $-2.152M ▲ $0 $5.064M ▲ $2.912M ▲ $-2.152M ▲
Q2-2025 $-4.335M ▼ $-2.397M ▼ $0 $125.1K ▼ $-2.272M ▼ $-2.397M ▼
Q1-2025 $-3.058M ▼ $-2.366M ▼ $0 ▼ $6.102M ▲ $3.735M ▲ $-2.366M ▼
Q4-2024 $-3.012M ▼ $-1.437M ▲ $100K ▲ $731.971K ▼ $-604.568K ▼ $-1.437M ▲
Q3-2024 $-1.829M $-1.893M $0 $1.475M $-417.622K $-1.893M

Five-Year Company Overview

Income Statement

Income Statement Coeptis is a classic early‑stage biotech story: it has essentially no product revenue yet and lives entirely on funding and research spending. The income statement is dominated by operating losses tied to development, overhead, and public-company costs. Losses have been persistent and, on a per‑share basis, have become heavier more recently, reflecting dilution and increased spending rather than any commercial traction. This profile is typical for a pre‑revenue biotech that is still years away from potential product launches and remains highly dependent on external capital to fund operations.

Balance Sheet

Balance Sheet The balance sheet is extremely thin, with only a small base of assets and effectively no reported cash cushion in the latest figures. There is no meaningful financial debt, which avoids leverage risk, but equity is very close to zero and has dipped negative in the past, signaling a fragile capital position. This combination suggests limited balance‑sheet flexibility and high dependence on new equity raises, partnerships, or other external funding to sustain development. Any delay or setback in financing could quickly become a key constraint for the business.

Cash Flow

Cash Flow Cash flows reflect a small but steady cash burn from operating activities, driven by research and corporate expenses rather than capital investment. There is virtually no spending on physical assets, so free cash flow is negative mainly because of the ongoing operating losses, not big build‑outs or facilities. While the absolute cash burn appears modest, it is large relative to the company’s tiny asset base and lack of cash on hand, underscoring financing risk. The company’s ability to continue funding its programs will likely hinge on raising capital or securing partners rather than internally generated cash for the foreseeable future.

Competitive Edge

Competitive Edge Competitively, Coeptis is positioned as a specialized, innovation‑driven cell therapy platform company in a very crowded and capital‑intensive space. Its strengths lie in differentiated technologies—universal and tunable CAR platforms, off‑the‑shelf natural killer cell therapies, and gene‑edited approaches that aim to work better with antibody drugs—plus strong academic partnerships and intellectual property rights. At the same time, it is up against far larger and better‑funded biopharma players pursuing similar cell and gene therapy targets. With no approved products and limited clinical data so far, its current competitive position is more about scientific promise and partnerships than commercial scale or market share.

Innovation and R&D

Innovation and R&D Innovation is the core of Coeptis’ story. The company is building multiple, complementary platforms: a universal, adapter‑based CAR system designed to be tunable and flexible; an off‑the‑shelf natural killer cell therapy sourced from donor cord blood; and gene‑edited NK cells that can be combined with existing antibody drugs without self‑destruction. These platforms target key pain points in cell therapy—safety, cost, speed of treatment, and resistance—while also exploring uses beyond cancer, including autoimmune and infectious diseases. Coeptis is also experimenting with an internal technology division focused on AI and automation, which is unusual for a company of this size and, if executed well, could streamline R&D. However, much of this remains pre‑commercial and subject to significant scientific, clinical, and regulatory uncertainty.

Summary

Overall, Coeptis looks like an ultra‑early‑stage biotech platform company: science‑heavy, revenue‑light, and financially fragile. Its financial statements show no commercial income, ongoing losses, and a very small, cash‑light balance sheet, which together imply a strong reliance on fresh capital and partnerships to keep advancing programs. On the strategic side, the company’s cell therapy platforms and academic collaborations provide meaningful scientific differentiation and multiple potential shots on goal, but all are still in the validation phase. The main swing factors going forward will likely be clinical trial results, the ability to sign or expand collaborations, and success in securing sustainable funding in a highly competitive and risky therapeutic area.